German family-owned drug major Boehringer Ingelheim is one of 35 partners from industry and academia who have come together to test innovative treatments for the prevention of Alzheimer’s dementia.
The European Prevention of Alzheimer’s Dementia (EPAD) Initiative is a five-year program as part of the Innovative Medicines Initiative, the joint undertaking between the EUuropean Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Partners include Novartis (NOVN: VX), Janssen, a subsidiary of Johnson & Johnson (NYSE: JNJ), and Amgen (Nasdaq: AMGN).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze